Weekly Highlights: Executive Changes at Three Pharma Companies; GSK Sells Nearly £1 Billion Worth of Haleon Shares
GSK
Pharmaceutical R&D Manufacturer
Fosun Pharmaceutical
Healthcare Industry Group
WANTAI BioPharm
Biological Diagnostic Reagents and Vaccine R&D, Manufacturer
BeOne
Developer of Molecular Targeted and Immune Anti-Tumor Drugs
AstraZeneca
Pharmaceutical Technology Research and Development Provider
Qilu Pharmaceutical
Specialty Formulations and Active Pharmaceutical Ingredients (API) Developer
"Weekly Highlights"
"Weekly Highlights" is a column launched by Siqi Club to summarize the major events in the pharmaceutical industry each week, covering the latest policy updates, news, pharmaceutical finance, drug approval progress, and other industry-related content.
Personnel Changes
HUMAN RESOURCES
Personnel Changes at Fosun Pharmaceutical
On January 17, Fosun Pharmaceutical released two announcements, respectively declaring: Effective January 17, 2024, Mr. Yuan Ning will no longer serve as the Vice President of Fosun Pharmaceutical; upon the nomination of the Chief Executive Officer, it was agreed to promote and appoint Ms. Feng Rongli and Ms. Li Jing (both previously serving as Senior Vice Presidents of the company) as Executive Presidents. The term of their new positions will commence on January 17, 2024, and end upon the expiration of the current Board of Directors' term.
WuXi Biologics Chief Technology Officer Retires
On January 15, WuXi Biologics announced that Zhou Weichang will retire on March 31 and step down from his positions as the company's Chief Technology Officer and President of Global Biopharmaceutical Development and Operations. Sherry Gu has been appointed and will assume the roles of Chief Technology Officer and Executive Vice President, Head of Biopharmaceutical Development and Manufacturing, after Zhou Weichang's retirement.
WANTAI BioPharm Appoints New General Manager
On the evening of January 15, WANTAI BioPharm announced that Qiu Zixin would apply to resign from his position as General Manager of the company. After resignation, he will continue to serve as the Chairman of the Board and related positions on the Board's special committees. Meanwhile, WANTAI BioPharm appointed Jiang Zhiming as the new General Manager.
Policy Brief
POLICY
Seven Prohibited Behaviors for Pharmaceutical Representatives Reinforced in One Region
On January 15, the Anhui Provincial Drug Administration released a message stating that the Seventh Branch had recently issued a "Reminder and Warning Letter on Regulating the Behavior of Pharmaceutical Representatives" to all pharmaceutical and medical device production and operation enterprises within its jurisdiction. The letter reminded enterprises to strengthen self-discipline, operate legally, and conduct business with integrity. It was mentioned that the "Reminder and Warning Letter" reiterated and clarified five prohibited behaviors for each drug marketing authorization holder and seven prohibited behaviors for pharmaceutical representatives.
Pharmaceutical News Updates
PHARMA
BeOne Medicines Announces Submission of the 15th Indication for Anti-PD-1 Monoclonal Antibody
On January 19, BeOne Medicines announced that the supplemental Biologics License Application (sBLA) for its PD-1 inhibitor tislelizumab for a new indication has been accepted by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA). The application is for perioperative treatment (covering neoadjuvant + adjuvant) in patients with resectable non-small cell lung cancer (NSCLC). According to BeOne Medicines' press release, in China, tislelizumab has cumulatively submitted 15 indication applications accepted by the CDE, of which 12 indications have been approved by the NMPA.
World's First! AstraZeneca's First-in-Class Complement Factor D Inhibitor Approved for Marketing in Japan
On January 19, AstraZeneca announced that its first-in-class oral complement factor D inhibitor, Voydeya (danicopan), had been approved for marketing in Japan, achieving the world's first approval.
Qilu Pharmaceutical's ALK/ROS1 Inhibitor Approved for New Indication
On January 16, the official website of China's National Medical Products Administration (NMPA) announced that the new indication application for Irulast® submitted by Qilu Pharmaceutical has been officially approved.
Pharmaceutical Finance
BUSINESS
GSK Sells Nearly £1 Billion Worth of Haleon Shares
On January 17, GSK announced that it had agreed to sell 300 million shares of Haleon, a consumer healthcare company, at a price of 326 pence per share, raising £978 million.
RMB 3 Billion to Become the Largest Shareholder, Orion Enters the ADC Track
On January 15, South Korean confectionery company Orion Group will acquire 25.7% of LegoChem Biosciences for 550 billion Korean won (approximately 3 billion RMB), becoming the largest shareholder of this Nasdaq-listed biotechnology company.
Subject to 90 Million Telecom Fraud, Hepalink Receives Regulatory Attention Letter
On January 14, Hepalink announced that its wholly-owned subsidiary, Techdow Pharma Italy S.R.L. (referred to as "Tian Dao Italy"), had recently fallen victim to a telecommunications fraud scheme perpetrated by a criminal gang, involving an amount of approximately 11.7 million euros (about 91.86 million RMB). On January 15, Hepalink also received a regulatory attention letter from the Shenzhen Securities Regulatory Bureau.
ClickRead the Original Text Learn More